Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: Evaluation of potential chemopreventive activity

Clara Curiel-Lewandrowski, Susan M. Swetter, Janine G. Einspahr, Chiu Hsieh Hsu, Ray Nagle, Paul Sagerman, Joseph Tangrea, Howard Parnes, David S. Alberts, Hsiao Hui Chow

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

BACKGROUND: Reduced melanoma risk has been reported with regular use of nonsteroidal anti-inflammatory drugs (NSAIDs). However, the ability of NSAIDs to reach melanocytes in vivo and modulate key biomarkers in preneoplastic lesions such as atypical nevi has not been evaluated. METHODS: This randomized, double-blind, placebo-controlled trial of sulindac was conducted in individuals with atypical nevi (AN) to determine bioavailability of sulindac and metabolites in nevi and effect on apoptosis and vascular endothelial growth factor A (VEGFA) expression in AN. Fifty subjects with AN ≥4 mm in size and 1 benign nevus (BN) were randomized to sulindac (150 mg twice a day) or placebo for 8 weeks. Two AN were randomized for baseline excision, and 2 AN and BN were excised after intervention. RESULTS: Postintervention sulindac, sulindac sulfone, and sulindac sulfide concentrations were 0.31 ± 0.36, 1.56 ± 1.35, and 2.25 ± 2.24 μg/mL in plasma, and 0.51 ± 1.05, 1.38 ± 2.86, and 0.12 ± 0.12 μg/g in BN, respectively. Sulindac intervention did not significantly change VEGFA expression but did increase expression of the apoptotic marker cleaved caspase-3 in AN (increase of 3 ± 33 in sulindac vs decrease of 25 ± 45 in the placebo arm, P =.0056), although significance was attenuated (P =.1103) after adjusting for baseline expression. CONCLUSIONS: Eight weeks of sulindac intervention resulted in high concentrations of sulindac sulfone, a proapoptotic metabolite, in BN but did not effectively modulate VEGFA and cleaved caspase-3 expression. Study limitations included limited exposure time to sulindac and the need to optimize a panel of biomarkers for NSAID intervention studies.

Original languageEnglish (US)
Pages (from-to)5848-5856
Number of pages9
JournalCancer
Volume118
Issue number23
DOIs
StatePublished - Dec 1 2012

Keywords

  • anti-inflammatory agents
  • atypical nevi
  • chemoprevention
  • melanoma
  • nevus
  • nonsteroidal
  • prevention and control

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: Evaluation of potential chemopreventive activity'. Together they form a unique fingerprint.

  • Cite this